Purpose
Gliomas are primary brain tumours that display histologic features of glial cells. The diffuse gliomas are the most common types. They are classified according to the 2016 World Health Organization (WHO) system by both histologic and molecular characteristics as isocitrate dehydrogenase (IDH)-mutant or IDH-wild type astrocytomas; IDH-mutant and 1p19q-co deleted oligodendrogliomas; and IDH-mutant or IDH-wild type glioblastomas (1).
Glioblastoma (GB) is the most malignant, aggressive and common form of primary brain cancer in adults, encompassing 16% of them (2). GB IDH-wild type corresponds most frequently...
Methods and materials
This is a prospective observational study. There were 147 consecutive patients with diffuse gliomas of the central nervous system in total, between January 2015 and December 2018. The inclusion criteria were:
A diagnostic MRI (1.5T or 3T system) study that includes: diffusion-weighted imaging with a b-value of 1000 s/mm2 and ADC map, post-contrast imaging, perfusion (Dynamic Susceptibility Contrast and Arterial Spin Labelling) and spectroscopy (CSI and Single-voxel spectroscopy).
Resection surgery and chemoradiotherapy treatment, according to their histopathology and genetics.
Genetic analysis that includes: Isocitrate-dehydrogenase-1 (IDH1)...
Results
The mean age of our sample was 53.9 ± 13.5, 58.5% of men and 41.5% of women. Regarding tumour location, 60.5% were located on the right hemispheric of the brain and 39.5% on the left. The most affected región was the frontal lobe (36%) followed by the temporal lobe (28%), the parietal lobe (21%) and the occipital lobe (15%), whereas 7.6% of patients had multicentric tumours. The grade and genetics of the diffuse glioma are illustrated in Fig. 1. Most of the tumours were WHO...
Conclusion
In this study, Imaging biomarkers obtained from advanced MRI sequences have good accuracy for identifying IDH-wild-type status in diffuse gliomas. thus improving the overall survival prediction and favouring more precise therapeutic decisions.
Personal information and conflict of interest
A. J. Barrios Lopez; Madrid/ES - nothing to disclose A. Palpán Flores; Madrid/ES - nothing to disclose A. Royo Orejas; Madrid/ES - nothing to disclose G. Garzón Moll; Madrid/ES - nothing to disclose J. M. Roda Frade; Madrid/ES - nothing to disclose C. Viváncos Sánchez; Madrid/ES - nothing to disclose E. Lanz Santos; Madrid/ES - nothing to disclose F. García Martínez; Madrid/ES - nothing to disclose C. Utrilla Contreras; Madrid/ES - nothing to disclose
References
WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985-96.
Hartmann C, Hentschel B, Simon M, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013; 19:5146.
Zhao H, Wang S, Song C, et al. The prognostic value of...
